玻璃体内注射药物对视网膜静脉阻塞的治疗(英文)

Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion

视网膜静脉阻塞( retinal vein occlusion,RVO) 是继糖尿病性视网膜病变之后最常见的影响视网膜的视觉致残性疾病。虽然该疾病实体早已被认定,但其治疗仍存在争议。黄斑水肿是该视网膜血管性疾病中视力下降 ( visual acuity,VA) 的主要原因。最近玻璃体腔已越来越多地被用来作为一个药物储物,通过玻璃体腔注射直接治疗黄斑水肿。迄今最广泛的注射药物为曲安奈德( triamcinolone acetonide,TA) 和贝伐单抗。该论文的目的是评估证据,并讨论最近有人提出的关于玻璃体内注射皮质类固醇和抗血管内皮生长因子的药物治疗对视网膜静脉阻塞是有效的基本原理。

Retinalvein occlusion（RVO） is the most common visually disabling disease affecting the retina after diabetic retinopathy.Although the disease entity has long been known,its management is still controversial.Macular edema is the main reason for decreased visual acuity（VA） in this retinal vascular disorder.Recently the vitreous cavity has increasingly been used as a reservoir of drugs for the direct treatment of macular edema through intravitreal injection route.The most widely injected drugs so far have been triamcinolone acetonide（TA） and bevacizumab.The objective of this review is to evaluate the evidence and discuss the rationale behind the recent suggestions that intravitreal pharmacotherapy by corticosteroids and anti-vascular endothelial growth factors may be useful in the treatment of retinal vein occlusion.